Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas

The BRAF(V600E) mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAF(V600E) mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouravan, Sarina, Meza-Zepeda, Leonardo A., Myklebost, Ola, Stratford, Eva W., Munthe, Else
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979358/
https://www.ncbi.nlm.nih.gov/pubmed/29570692
http://dx.doi.org/10.3390/ijms19040969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979358/
https://www.ncbi.nlm.nih.gov/pubmed/29570692
http://dx.doi.org/10.3390/ijms19040969

Ejemplares similares